The Long-Term PPI Worry, Sorted From Real to Overblown

What did the specialists actually conclude?

In 2017 the American Gastroenterological Association convened an expert review for exactly this question, and its best-practice advice came out in three parts: when a PPI is appropriately indicated, the benefits generally outweigh the risks; anyone taking one should be on the lowest effective dose; and there is not enough evidence to recommend routine strategies to mitigate the purported harms 1Ref 1Freedberg DE, Kim LS, Yang YX (2017).The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.That AGA best-practice advice holds long-term PPI benefits generally outweigh risks when appropriately indicated, that patients should be on the lowest effective dose, and that there is insufficient evidence to recommend routine strategies to mitigate purported PPI harms..

That third clause is the one that gets skipped, and it cuts in an uncomfortable direction. It does not say the risks were disproven. It says that no routine countermeasure — no standing screening test, no supplement taken as a hedge — earned a recommendation 1Ref 1Freedberg DE, Kim LS, Yang YX (2017).The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.That AGA best-practice advice holds long-term PPI benefits generally outweigh risks when appropriately indicated, that patients should be on the lowest effective dose, and that there is insufficient evidence to recommend routine strategies to mitigate purported PPI harms.. If you have been quietly wondering whether you ought to be monitoring something, the review's answer is that there is nothing established to monitor, not that monitoring was considered and found sufficient.

The "lowest effective dose" half is easier to act on than it sounds. It does not mean cutting pills or improvising. It means the dose is a live variable rather than a setting chosen once and never revisited 1Ref 1Freedberg DE, Kim LS, Yang YX (2017).The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.That AGA best-practice advice holds long-term PPI benefits generally outweigh risks when appropriately indicated, that patients should be on the lowest effective dose, and that there is insufficient evidence to recommend routine strategies to mitigate purported PPI harms.. For a lot of people who have taken the same prescription for years, nobody has revisited it because nothing in the system prompted anyone to.

The guidance is conditional, and the condition is the word indicated. Everything below hangs on it.

The whole sentence turns on "appropriately indicated." A PPI prescribed for erosive esophagitis and a PPI still being refilled eight years after a two-month course for a stomach bug that resolved are the same molecule sitting in two entirely different risk-benefit calculations. Only one of them has a benefit on the other side of the scale.

Why does every PPI headline sound so alarming?

Because the studies behind them are almost all observational, and observational data about a drug this common has a structural problem it cannot escape. Researchers compare people taking PPIs to people who are not, count how many in each group develop kidney disease or dementia or a fracture, and report the difference. What that design cannot do is tell you whether the drug caused the difference or the reason for the drug did.

Confounding by indication means the illness that led to the prescription — not the prescription — produces the outcome you measured. PPIs are close to a worst case for it. People on long-term acid suppression are, on average, older, heavier, on more medications, and more likely to carry other chronic disease than people who take nothing. Every one of those things independently predicts kidney disease, fractures, infections, and dementia. Statistical adjustment shaves at the problem; it does not solve it, because you can only adjust for what you thought to measure.

Picture two people the same age. One has taken a PPI for twelve years; the other has never needed one. The first arrived at that prescription through a body that was already generating problems — reflux severe enough to medicate, often alongside weight, other prescriptions, other diagnoses. The comparison was never between two identical people differing by one pill. It was between two different populations, one of which was sicker before the first tablet.

The result is a literature that reliably generates a headline and rarely generates an answer. The AGA's review of that whole body of work landed on benefits outweighing risks for indicated use, rather than on any specific harm being confirmed 1Ref 1Freedberg DE, Kim LS, Yang YX (2017).The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.That AGA best-practice advice holds long-term PPI benefits generally outweigh risks when appropriately indicated, that patients should be on the lowest effective dose, and that there is insufficient evidence to recommend routine strategies to mitigate purported PPI harms.. The individual worries each have their own literature and their own weak points — ppis and bone loss, ppis and kidney disease, ppis and infection risk, and ppis and nutrient levels are the four that come up most, and each deserves reading on its own terms rather than as one undifferentiated cloud of dread.

Reading a risk headline about yourself

Two translation errors turn a modest paper into a frightening one, and both are worth learning to spot, because they will recur for every drug you are ever prescribed. The first is relative risk read as absolute risk. The second is a population average read as a personal forecast. Neither is a flaw in the research. Both happen in the gap between the paper and the reader.

Relative versus absolute. When a study reports a risk raised by some proportion, that proportion is relative to a baseline. Doubling something rare leaves you with something rare. A headline can say a risk is doubled and be technically accurate while the change in any individual's odds stays very small — and headlines rarely print the baseline, because the baseline is what makes the number boring. Without it, the percentage is unreadable.

Population versus person. An association measured across a cohort describes the cohort. It does not forecast you, and it is not even the same kind of statement. A study can be perfectly valid and still be poor at predicting any individual's outcome. Those are two different properties.

Neither error is a reason to dismiss the research. They are reasons to ask what a finding actually says before deciding what it means for you. The AGA's review is, in effect, that work already done by people who read all of it — and the conclusion was that indicated use comes out ahead 1Ref 1Freedberg DE, Kim LS, Yang YX (2017).The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.That AGA best-practice advice holds long-term PPI benefits generally outweigh risks when appropriately indicated, that patients should be on the lowest effective dose, and that there is insufficient evidence to recommend routine strategies to mitigate purported PPI harms..

The question that outranks the entire risk list

Whether you still have a reason to be taking it. In 2022 the AGA published a clinical practice update devoted specifically to deprescribing PPIs, and its central advice is that people without a clear ongoing indication should attempt to stop or step down 2Ref 2Targownik LE, Fisher DA, Saini SD (2022).AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review.That patients without a clear ongoing indication should attempt to stop or step down their PPI, while those with erosive esophagitis, Barrett's esophagus, or bleeding-risk indications should continue.. That is a striking thing for a guideline to say, and it reframes the worry entirely.

Here is why it outranks the risk list. Every risk, however small and however uncertain, is being carried for nothing if there is no benefit on the other side. You do not need to resolve whether the kidney association is causal in order to conclude that a drug you have no reason to take is a drug not worth taking. The uncertainty stops mattering the moment the indication is gone.

And indications disappear quietly. The prescription that started as an eight-week trial for heartburn — the exact trial the ACG recommends for classic heartburn or regurgitation without alarm features 3Ref 3Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ (2022).ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease.That the ACG recommends an 8-week empiric once-daily PPI trial for classic heartburn or regurgitation without alarm features — a course with a defined endpoint rather than an open-ended prescription. — has an endpoint written into it. Someone was supposed to reassess at eight weeks. Very often nobody did, the refills kept authorising, and the trial became a decade.

The ACG's empiric PPI course for uncomplicated reflux is eight weeks — a trial with an end date, not a standing prescription 3Ref 3Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ (2022).ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease.That the ACG recommends an 8-week empiric once-daily PPI trial for classic heartburn or regurgitation without alarm features — a course with a defined endpoint rather than an open-ended prescription..

If you are trying to work out where you personally sit, the useful reading is not another catalogue of long term PPI use risks. It is the deprescribing question, which fits in one sentence: what was this started for, and is that thing still true?

Who is meant to stay on one indefinitely

Some people are, and the deprescribing update is explicit about it: those with erosive esophagitis, Barrett's esophagus, or an indication related to bleeding risk should continue 2Ref 2Targownik LE, Fisher DA, Saini SD (2022).AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review.That patients without a clear ongoing indication should attempt to stop or step down their PPI, while those with erosive esophagitis, Barrett's esophagus, or bleeding-risk indications should continue.. For these readers the calculus genuinely inverts. The PPI is not a comfort measure that drifted into permanence — it is treating or preventing something with consequences considerably more definite than any association in the headlines.

Barrett's esophagus is the clearest case. It is a complication of chronic reflux and the only known precursor to esophageal adenocarcinoma, and the ACG's guideline includes PPI therapy for people who have it 4Ref 4Shaheen NJ, Falk GW, Iyer PG, Souza RF, Yadlapati RH, Sauer BG, Wani S (2022).Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline.That Barrett's esophagus is a complication of chronic GERD and the only known precursor to esophageal adenocarcinoma, that PPI therapy is recommended in patients with Barrett's, and that a single screening endoscopy is recommended for chronic GERD plus three or more risk factors.. Barrett's esophagus is a change in the lining of the lower esophagus caused by years of acid exposure. A person with Barrett's who stops a PPI because of a newspaper story has traded a contested association for a documented precursor relationship. That is not a cautious trade. It only looks like one.

The same guideline is why some people with long-standing reflux are offered a single screening endoscopy in the first place: chronic GERD plus three or more risk factors is the ACG's threshold for looking 4Ref 4Shaheen NJ, Falk GW, Iyer PG, Souza RF, Yadlapati RH, Sauer BG, Wani S (2022).Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline.That Barrett's esophagus is a complication of chronic GERD and the only known precursor to esophageal adenocarcinoma, that PPI therapy is recommended in patients with Barrett's, and that a single screening endoscopy is recommended for chronic GERD plus three or more risk factors.. Where Barrett's is found, barrett's surveillance follows its own intervals and its own logic, and the PPI is part of the package rather than an optional extra.

The point is not that everyone should stay on. It is that "long-term PPI user" is not one population. It is at least two, and they should not read the same headline the same way. The uncomfortable part is that the people in the continue group do not always know they are in it, because the endoscopy that sorted them may have happened years ago and been filed as a normal-sounding result.

The reflux a PPI was never going to fix

A sizeable share of long-term PPI use is treating something the drug has a poor chance of touching. When reflux is suspected behind a chronic cough, hoarseness, or constant throat clearing — the extraesophageal presentations — the AGA's 2023 update is blunt about the state of play: there is no single confirmatory test, diagnosis rests on a global clinical impression, and empiric PPI therapy is low-yield when typical GERD symptoms are absent 5Ref 5Chen JW, Vela MF, Peterson KA, Carlson DA (2023).AGA Clinical Practice Update on the Diagnosis and Management of Extraesophageal Gastroesophageal Reflux Disease: Expert Review.That for suspected extraesophageal reflux there is no single confirmatory test, diagnosis rests on global clinical impression, and empiric PPI therapy is low-yield when typical GERD symptoms are absent..

Low-yield is the phrase worth sitting with. It describes a large number of people who were started on a PPI for a cough, whose cough did not clearly improve, who stayed on the drug anyway because stopping felt riskier than continuing, and who now count themselves among the long-term users worried about the headlines. They are carrying whatever the risk turns out to be in exchange for a benefit that was unlikely from the start 5Ref 5Chen JW, Vela MF, Peterson KA, Carlson DA (2023).AGA Clinical Practice Update on the Diagnosis and Management of Extraesophageal Gastroesophageal Reflux Disease: Expert Review.That for suspected extraesophageal reflux there is no single confirmatory test, diagnosis rests on global clinical impression, and empiric PPI therapy is low-yield when typical GERD symptoms are absent..

It also explains a peculiar loop. Absence of improvement gets read as "the reflux must be worse than we thought" rather than "the reflux may not be the cause," and the response is to continue rather than to reconsider. The AGA's framing — no confirmatory test, diagnosis by global clinical impression 5Ref 5Chen JW, Vela MF, Peterson KA, Carlson DA (2023).AGA Clinical Practice Update on the Diagnosis and Management of Extraesophageal Gastroesophageal Reflux Disease: Expert Review.That for suspected extraesophageal reflux there is no single confirmatory test, diagnosis rests on global clinical impression, and empiric PPI therapy is low-yield when typical GERD symptoms are absent. — is what makes that loop possible. Without a test that can come back negative, nothing ever closes the hypothesis, and the prescription outlives the question that produced it.

This is the least discussed pathway into a decade of acid suppression, and it is the one most worth naming out loud at the next appointment. The question is not "is this drug dangerous." It is "did this drug ever do anything for the thing I take it for?"

What the worry is legitimately pointing at

At something real, even if not at what the headlines claim. Long-term acid suppression is a genuine physiologic intervention taken daily for years, and an absence of established harm is not the same thing as established safety. The AGA's own advice includes the lowest effective dose precisely because uncertainty is not the same as reassurance 1Ref 1Freedberg DE, Kim LS, Yang YX (2017).The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.That AGA best-practice advice holds long-term PPI benefits generally outweigh risks when appropriately indicated, that patients should be on the lowest effective dose, and that there is insufficient evidence to recommend routine strategies to mitigate purported PPI harms..

The legitimate core of the worry is drift. A PPI is unusually easy to keep taking: it works, it is inexpensive, refills authorise without a visit, and no symptom ever announces that the indication expired. Nothing in the system prompts a reassessment. The worry that brings people to a page like this is often, underneath, an accurate perception that a decision was made once and never revisited — and that perception is correct even where the pharmacology turns out to be benign. Trust it that far. It is pointing at a real gap in your care, just not the one you thought.

What the worry does not justify is a unilateral stop, and it particularly does not justify one by the people most likely to attempt it. If worry is what is driving the impulse, the mechanics of tapering off a ppi belong in a conversation with the prescriber, where the indication gets checked first. The order matters: establish whether there is a reason to take it, then decide how to come off it. Reversing those two steps is how somebody with erosive esophagitis quietly stops treating it.

What to ask at the next appointment

Four questions turn a vague dread into a decision, and none of them require you to have resolved the science yourself. They put the burden where it belongs — on the record of why the drug was started, and whether that reason survived the years since.

• What was this originally prescribed for, and is that still true? This is the entire deprescribing question in one sentence 2Ref 2Targownik LE, Fisher DA, Saini SD (2022).AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review.That patients without a clear ongoing indication should attempt to stop or step down their PPI, while those with erosive esophagitis, Barrett's esophagus, or bleeding-risk indications should continue..
• Was there ever an endoscopy, and did it show erosive esophagitis or Barrett's? The answer sorts you into the continue group or the reassess group 2Ref 2Targownik LE, Fisher DA, Saini SD (2022).AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review.That patients without a clear ongoing indication should attempt to stop or step down their PPI, while those with erosive esophagitis, Barrett's esophagus, or bleeding-risk indications should continue..
• If there is no clear indication, are we stepping down or stopping — and what is the plan if symptoms return? A plan for the return is what makes the attempt survivable.
• Is there anything you would monitor while I stay on it? Expect the honest answer to be no. The AGA's review found insufficient evidence to recommend routine mitigation strategies 1Ref 1Freedberg DE, Kim LS, Yang YX (2017).The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.That AGA best-practice advice holds long-term PPI benefits generally outweigh risks when appropriately indicated, that patients should be on the lowest effective dose, and that there is insufficient evidence to recommend routine strategies to mitigate purported PPI harms., which means a clinician declining to order a standing test is following the evidence rather than dismissing you.

One more thing is worth raising if your symptoms have changed rather than merely persisted. Indigestion or reflux that begins or shifts after 60, or that arrives alongside weight loss, bleeding, or trouble swallowing, is the situation where the ACG and CAG guideline points to upper endoscopy rather than another medication trial 6Ref 6Moayyedi P, Lacy BE, Andrews CN, Enns RA, Howden CW, Vakil N (2017).ACG and CAG Clinical Guideline: Management of Dyspepsia.That upper endoscopy rather than a further empiric medication trial is indicated for dyspepsia in patients aged 60 and over or with alarm features such as weight loss, bleeding, or dysphagia.. That is a different conversation from the long-term-safety one, and it is the more time-sensitive of the two.